MDR-1339

N/A

Report date: 2023/01/03 18:04:14
NME

Base Information

Drug NameMDR-1339
Drug Alias NameDBT-1339MDR-1339
ClassificationNatural product/ExtractSmall molecules
Mechanisms of ActionBeta amyloid A4 protein aggregation inhibitors
TargetsBeta amyloid A4 protein
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMedifron
China Registration ClassN/A

Develop Information

Active CompaniesMedifronDaewoong Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsAlzheimer Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A